Insulet sees Q4 revenue growth 12%-15%

For the quarter ending December 31, 2024, the Company expects revenue growth of 12% to 15%. Revenue growth ranges by product line are: Total Omnipod of 13% to 16%; U.S. Omnipod of 9% to 12%; International Omnipod of 30% to 33%; Drug Delivery of (20)% to (15)%